---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000061"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:48:40.018711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated

## Summary
- Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.
- Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.
- First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.
- Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced.

## SEC filing metadata
- accession: 0001576885-24-000061
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/0001576885-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/abos-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000061
- JSON: https://secwatch.observer/filing/0001576885-24-000061.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000061.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.
  - Period: first quarter of 2024
  - Net income: $14.9 million
  - Result: reported results
  source text: Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000061/0001576885-24-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.